You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study

Article metrics

Article menu
Download PDFPDF
Oral Communication 2 – Cervical Cancer
Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study

 

Online download statistics by month:

Online download statistics by month: November 2019 to April 2024

AbstractFullPdf
Nov 20194802
Dec 20192300
Jan 20207206
Feb 20207005
Mar 20201603
Apr 20202203
May 20208803
Jun 20206804
Jul 20206101
Aug 20202800
Sep 20207001
Oct 2020138013
Nov 202014604
Dec 20208806
Jan 20215402
Feb 20214801
Mar 20218803
Apr 20217804
May 20212100
Jun 2021002
Jul 2021003
Aug 2021002
Sep 2021006
Oct 20214808
Nov 20213602
Dec 20213402
Jan 20223401
Feb 20224201
Mar 20223601
Apr 20224400
May 20225001
Jun 20224200
Jul 202214002
Aug 20225002
Sep 20224600
Oct 20222800
Nov 20225502
Dec 20222001
Jan 20233401
Feb 20233602
Mar 20237804
Apr 20237800
May 20233100
Jun 20233400
Jul 20232200
Aug 20233000
Sep 20235200
Oct 20232400
Nov 20233000
Dec 20232801
Jan 20241000
Feb 20242200
Mar 20247200
Apr 20241500
Total25280105